Abnormalities of liver biochemistry in COVID-19 are generally characterized by slight (1-2 times the superior limit of normal) increases in alanin-aminotransferaze (ALT) aspartat-aminotransferaze (AST) levels, reported in approximately 40–60% of pacients. The gene discussed is GPT; the disease is COVID-19.